POLAR ACS: bio-absorbable platform in acute coronary syndromes

Bio-absorbable devices are considered safe and effective for stable patients but there is still little information regarding their use in acute patients. ACS POLAR Register (POLishAbsorb Registry for ACS Patients) is a multicenter study which included 88 patients undergoing acute coronary syndrome without ST elevation who received a bio-absorbable platform. The aim of the study was to evaluate the safety and efficacy of the device and the occurrence of clinical events during hospitalization. Pre-vessel dilation was highly recommended. All patients completed the procedure with a TIMI 3 flow and only one needed a new emergency angioplasty. 

Conclusion: Initial registry showed that the implantation of these devices in patients with acute coronary syndromes is safe. The study aims to include 100 patients before publishing. 

Editorial comment: A predilate need to implement these devices can be a disadvantage for acute patients with unstable plaques. As we gain more experience with these platforms a better selection will be possible, those stable as well as those undergoing acute coronary syndrome.

dariusz_dudek_europcr
Dariusz Dudek, MD.
2013-05-22

Original title: Bioresorbable vascular scaffolds in patients with ACS – The multicenter registry in Poland: POLAR ACS.

 

More articles by this author

REPRISE II: results obtained with the new valve according to VARC criteria

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical...

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being almost the rule. The TriGuard EDD device...

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis...

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...